Meeting
2015 Gastrointestinal Cancers Symposium
Randomized phase III study of panitumumab (pmab) vs. cetuximab (cmab) in chemorefractory wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC): Outcomes by hypomagnesemia (hypomag) in ASPECCT.
Authors
Timothy Jay Price
Queen Elizabeth Hospital, University of Adelaide, Woodville, Australia
Timothy Jay Price , Marc Peeters , Tae Won Kim , Jin Li , Stefano Cascinu , Paul Ruff , Attili Venkatasatya Suresh , Anne Thomas , Sergei Tjulandin , Kathy Zhang , Roger Sidhu , Swaminathan Murugappan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT00788957
Citation
J Clin Oncol 33, 2015 (suppl 3; abstr 705)
DOI
10.1200/jco.2015.33.3_suppl.705
Abstract #
705
Poster Bd #
D47
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Randomized phase 3 study of panitumumab (pmab) vs cetuximab (cmab) in chemorefractory wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC): outcomes by hypomagnesemia (hypomag) in ASPECCT.
First Author: Marc Peeters
Poster
2016 Gastrointestinal Cancers Symposium
Outcomes by hypomagnesemia (hypomag) in the randomized phase III ASPECCT trial of patients (pts) with chemofractory wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC).
First Author: Marc Peeters
Poster
2015 Gastrointestinal Cancers Symposium
Prevalence and outcomes of patients (pts) with EGFR S492R ectodomain mutations in ASPECCT: Panitumumab (pmab) vs. cetuximab (cmab) in pts with chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer (mCRC).
First Author: Timothy Jay Price
Poster
2018 Gastrointestinal Cancers Symposium
Panitumumab versus cetuximab in patients with wild-type KRAS exon 2 metastatic colorectal cancer who received prior bevacizumab therapy: A combined analysis of individual patient data from ASPECCT and WJOG6510G.
First Author: Hiroya Taniguchi